HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.

Abstract
The molecular and neuronal substrates conferring on clozapine its unique and superior efficacy in the treatment of schizophrenia remain elusive. The interaction of clozapine with many G protein-coupled receptors is well documented but less is known about its biologically active metabolite, N-desmethylclozapine. Recent clinical and preclinical evidences of the antipsychotic activity of the muscarinic agonist xanomeline prompted us to investigate the effects of N-desmethylclozapine on cloned human M1-M5 muscarinic receptors. N-desmethylclozapine preferentially bound to M1 muscarinic receptors with an IC50 of 55 nM and was a more potent partial agonist (EC50, 115 nM and 50% of acetylcholine response) at this receptor than clozapine. Furthermore, pharmacological and site-directed mutagenesis studies suggested that N-desmethylclozapine preferentially activated M1 receptors by interacting with a site that does not fully overlap with the acetylcholine orthosteric site. As hypofunction of N-methyl-d-aspartate (NMDA) receptor-driven neuronal ensembles has been implicated in psychotic disorders, the neuronal activity of N-desmethylclozapine was electrophysiologically investigated in hippocampal rat brain slices. N-desmethylclozapine was shown to dose-dependently potentiate NMDA receptor currents in CA1 pyramidal cells by 53% at 100 nM, an effect largely mediated by activation of muscarinic receptors. Altogether, our observations provide direct evidence that the brain penetrant metabolite N-desmethylclozapine is a potent, allosteric agonist at human M1 receptors and is able to potentiate hippocampal NMDA receptor currents through M1 receptor activation. These observations raise the possibility that N-desmethylclozapine contributes to clozapine's clinical activity in schizophrenics through modulation of both muscarinic and glutamatergic neurotransmission.
AuthorsCyrille Sur, Pierre J Mallorga, Marion Wittmann, Marlene A Jacobson, Danette Pascarella, Jacinta B Williams, Philip E Brandish, Douglas J Pettibone, Edward M Scolnick, P Jeffrey Conn
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 100 Issue 23 Pg. 13674-9 (Nov 11 2003) ISSN: 0027-8424 [Print] United States
PMID14595031 (Publication Type: Journal Article)
Chemical References
  • DNA, Complementary
  • Receptor, Muscarinic M1
  • Receptors, N-Methyl-D-Aspartate
  • norclozapine
  • Guanosine 5'-O-(3-Thiotriphosphate)
  • Clozapine
Topics
  • Allosteric Site
  • Animals
  • Brain (metabolism)
  • Cell Line
  • Clozapine (analogs & derivatives, pharmacology)
  • Cricetinae
  • DNA, Complementary (metabolism)
  • Dose-Response Relationship, Drug
  • Electrophysiology
  • Guanosine 5'-O-(3-Thiotriphosphate) (metabolism)
  • Hippocampus (metabolism)
  • Humans
  • Inhibitory Concentration 50
  • Mutagenesis, Site-Directed
  • Neurons (metabolism)
  • Protein Binding
  • Rats
  • Receptor, Muscarinic M1 (agonists, chemistry)
  • Receptors, N-Methyl-D-Aspartate (metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: